Cite as: N. R. Faria *et al.*, *Science*
10.1126/science.abh2644 (2021).

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Nuno R. Faria^{1,2,3*†}, Thomas A. Mollan^{1†}, Charles Whittaker^{1†}, Ingra M. Claro^{2,4†}, Darlan da S. Candido^{2,3†}, Swapnil Mishra^{1†}, Myuki A. E. Crispim^{5,6}, Flavia C. S. Sales^{2,4}, Iwona Hawryluk¹, John T. McCrone⁷, Ruben J. G. Hulswit⁸, Lucas A. M. Franco^{2,4}, Mariana S. Ramundo^{2,4}, Jaqueline G. de Jesus^{2,4}, Pamela S. Andrade⁹, Thais M. Coletti^{2,4}, Giulia M. Ferreira¹⁰, Camila A. M. Silva^{2,4}, Erika R. Manuli^{2,4}, Rafael H. M. Pereira¹¹, Pedro S. Peixoto¹¹, Moritz U. G. Kraemer³, Nelson Gaburo Jr¹³, Cecilia da C. Camilo¹³, Henrique Hoeltgebaum¹⁵, William M. Souza¹⁶, Esmeria C. Rocha^{2,4}, Leandro M. de Souza^{2,4}, Mariana C. de Pinho^{2,4}, Leonardo J. T Araujo¹⁷, Frederico S. V. Malta¹⁸, Aline B. de Lima¹⁸, Joice do P. Silva¹⁸, Danielle A. G. Zauli¹⁸, Alessandro C. de S. Ferreira¹⁸, Ricardo P. Schnekenberg¹⁹, Daniel J. Laydon¹, Patrick G. T. Walker¹, Hannah M. Schlüter¹⁵, Ana L. P. dos Santos¹⁴, Maria S. Vidal¹⁴, Valentina S. Del Caro¹⁴, Rosinaldo M. F. Filho¹⁴, Helem M. dos Santos¹⁴, Renato S. Aguiar²⁰, José L. Proença-Modena²¹, Bruce Nelson²², James A. Hay^{23,24}, Mélodie Monod¹⁵, Xenia Miskouridou¹⁵, Helen Coupland¹, Raphael Sonabend¹, Michaela Vollmer¹, Axel Gandy¹⁵, Carlos A. Prete Jr.²⁵, Vitor H. Nascimento²⁵, Marc A. Suchard²⁶, Thomas A. Bowden⁸, Sergei L. K. Pond²⁷, Chieh-Hsi Wu²⁸, Oliver Ratmann¹⁵, Neil M. Ferguson¹, Christopher Dye³, Nick J. Loman²⁹, Philippe Lemey³⁰, Andrew Rambaut⁷, Nelson A. Fraiji^{5,31}, Maria do P. S. S. Carvalho^{5,32}, Oliver G. Pybus^{3,33†}, Seth Flaxman^{15†}, Samir Bhatt^{1,34*†}, Ester C. Sabino^{2,4*†}

¹MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, UK. ²Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. ³Department of Zoology, University of Oxford, UK. ⁴Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. ⁵Fundação Hospitalar de Hematologia e Hemoterapia, Manaus, Brazil. ⁶Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia, Manaus, Brazil. ⁷Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK. ⁸Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. ⁹Departamento de Epidemiologia, Faculdade de Saúde Pública da Universidade de São Paulo, São Paulo, Brazil. ¹⁰Laboratório de Virologia, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, Brazil. ¹¹Institute for Applied Economic Research—Ipea, Brasília, Brazil. ¹²Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil. ¹³DB Diagnósticos do Brasil, São Paulo, Brazil. ¹⁴CDL Laboratório Santos e Vidal, Manaus, Brazil. ¹⁵Department of Mathematics, Imperial College London, UK. ¹⁶Virology Research Centre, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. ¹⁷Laboratory of Quantitative Pathology, Center of Pathology, Adolfo Lutz Institute, São Paulo, Brazil. ¹⁸Instituto Hermes Pardini, Brazil. ¹⁹Nuffield Department of Clinical Neurosciences, University of Oxford, UK. ²⁰Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ²¹Laboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP), São Paulo, Brazil. ²²Instituto Nacional de Pesquisas da Amazônia, Manaus, Brazil. ²³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ²⁴Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ²⁵Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil. ²⁶Department of Biomathematics, Department of Biostatistics and Department of Human Genetics, University of California, Los Angeles, CA, USA. ²⁷Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, PA, USA. ²⁸Mathematical Sciences, University of Southampton, Southampton, UK. ²⁹Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK. ³⁰Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium. ³¹Diretoria Clínica, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil. ³²Diretoria da Presidência, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil. ³³Department of Pathobiology and Population Sciences, The Royal Veterinary College, London, UK. ³⁴Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark.

†These authors contributed equally to this work.

†These authors contributed equally to this work.

*Corresponding author. Email: n.faria@imperial.ac.uk (N.R.F.); samir.bhatt@sund.ku.dk (S.B.); sabinoec@usp.br (E.S.C.)

Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite previously high levels of infection. Genome sequencing of viruses sampled in Manaus between November 2020 and January 2021 revealed the emergence and circulation of a novel SARS-CoV-2 variant of concern. Lineage P.1, acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor. Molecular clock analysis shows that P.1 emergence occurred around mid-November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.7–2.4-fold more transmissible, and that previous (non-P.1) infection provides 54–79% of the protection against infection with P.1 that it provides against non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.

Brazil has experienced high mortality during the COVID-19 pandemic, recording >300,000 deaths and >13 million reported cases, as of March 2020. SARS-CoV-2 infection and disease burden have been highly variable across the country, with Amazonas state in north Brazil being the worst-affected region (1). Serological surveillance of blood donors in Manaus, the capital city of Amazonas and the largest city in the Amazon region, has suggested >67% cumulative attack rates by October 2020 (2). Similar but slightly lower seroprevalences have also been reported for cities in neighboring regions (3, 4). However, the level of previous infection in Manaus was clearly not sufficient to prevent a rapid resurgence in SARS-CoV-2 transmission and mortality there during late 2020 and early 2021 (5), which has placed a significant pressure on the city's healthcare system.

Here, we show that the second wave of infection in Manaus was associated with the emergence and rapid spread of a new SARS-CoV-2 lineage of concern, named lineage P.1. The lineage carries a unique constellation of mutations (table S1), including several that have been previously determined to be of virological importance (6–10) and which are located in the spike protein receptor binding domain (RBD), the region of the virus involved in recognition of the angiotensin-converting enzyme-2 cell surface receptor (11). Using genomic data, structure-based mapping of mutations of interest onto the spike protein, and dynamical epidemiology modelling of genomic and mortality data, we investigate the emergence of the P.1 lineage and explore epidemiological explanations for the resurgence of COVID-19 in Manaus.

Identification and nomenclature of a novel P.1 lineage in Manaus

In late 2020, two SARS-CoV-2 lineages of concern were discovered through genomic surveillance, both characterised by sets of significant mutations: lineage B.1.351, first reported in South Africa (12) and lineage B.1.1.7, detected in the United Kingdom (13). Both variants have transmitted rapidly in the countries where they were discovered and spread to other regions (14, 15). Analyses indicate B.1.1.7 has higher transmissibility and causes more severe illness compared with previously circulating lineages in the UK (1, 16, 17).

Following a rapid increase in hospitalizations in Manaus caused by severe acute respiratory infection in December 2020 (Fig. 1A), we focused ongoing SARS-CoV-2 genomic surveillance (2, 18–22) on recently collected samples from the city (supplementary materials, materials and methods, and table S2). Prior to this, only seven SARS-CoV-2 genome sequences from Amazonas state were publicly available (SARS-CoV-2 was first detected in Manaus on 13 March 2020) (19, 23). We sequenced SARS-CoV-2 genomes from 184 samples from patients seeking COVID-19 testing in two diagnostic laboratories in Manaus between November and December

2020, using the ARTIC V3 multiplexed amplicon scheme (24) and the MinION sequencing platform. As partial genome sequences can provide useful epidemiological information, particularly regarding virus genetic diversity and lineage composition (25), we harnessed information from partial ($n=41$, 25–75% genome coverage), as well as near-complete ($n=95$, 75–95%) and complete ($n=48$, $\geq 95\%$) sequences from Manaus (figs. S1 to S4), together with other available and published genomes from Brazil for context. Viral lineages were classified using the Pangolin (26) software tool (<http://pangolin.cog-uk.io/>), nextclade (<https://clades.nextstrain.org/>) and standard phylogenetic analysis using complete reference genomes.

Our early data indicated the presence of a novel SARS-CoV-2 lineage in Manaus containing 17 amino acid changes (including 10 in the spike protein), three deletions, four synonymous mutations and a four base-pair nucleotide insertion compared to the most closely related available sequence (GISAID ID: EPI_ISL_722052) (27) (Fig. 1B) (lineage-defining mutations can be found in table S1). This lineage was given a new designation, P.1, on the basis that (i) it is phylogenetically and genetically distinct from ancestral viruses, (ii) associated with rapid spread in a new area, and (iii) carries a constellation of mutations that may have phenotypic relevance (26). Phylogenetic analysis indicated that P.1, and another lineage, P.2 (19), were descendants of lineage B.1.1.28 that was first detected in Brazil in early March 2020 (Fig. 1B). Our preliminary results were shared with local teams on 10 Jan 2021 and published online on 12 Jan 2021 (27). Concurrently, cases of SARS-CoV-2 P.1 infection were reported in Japan in travellers from Amazonas (28). As of 24 Feb 2021, P.1 had been confirmed in 6 Brazilian states, which in total received >92,000 air passengers from Manaus in November 2020 (Fig. 1C). Genomic surveillance first detected lineage P.1 on 6 December 2020 (Fig. 1A), after which the frequency of P.1 relative to other lineages increased rapidly in the tested samples from Manaus (Fig. 1D; lineage frequency information can be found in fig. S5). Retrospective genome sequencing might be able to recover earlier P.1 genomes. Between the 2 Nov 2020 and 9 Jan 2021, we observed 7,137 SARI cases and 3,144 SARI deaths in Manaus (Fig. 1A). We generated a total of 182 SARS-CoV-2 sequences from Manaus during this period. This corresponds to 1 genome for each 39 SARI cases in Manaus, and this ratio is >100-fold higher compared to the average number of shared genomes per reported case during the same period in Brazil.

Dating the emergence of the P.1 lineage

We used molecular clock phylogenetics to understand the emergence and evolution of lineage P.1 (25). We first regressed root-to-tip genetic distances against sequence sampling dates (29) for the P.1, P.2, and B.1.1.28 lineages

separately (figs. S6 to S8). This exploratory analysis revealed similar evolutionary rates within each lineage, but greater root-to-tip distances for P.1 compared to B.1.1.28 (fig. S8), suggesting that the emergence of P.1 was preceded by a period of faster molecular evolution. The B.1.1.7 lineage exhibits similar evolutionary characteristics (13), which was hypothesized to have occurred in a chronically infected or immunocompromised patient (30, 31).

To date the emergence of P.1, while accounting for a faster evolutionary rate along its ancestral branch, we used a local molecular clock model (32) with a flexible non-parametric demographic tree prior (33). Using this approach, we estimate the date of the common ancestor of the P.1 lineage to be around 15 Nov 2020 (median, 95% Bayesian credible interval, BCI, 6 Oct to 24 Nov 2020, mean, 9 Nov 2020) (fig. S9). This is only three to four weeks before the resurgence in SARS-CoV-2 confirmed cases in Manaus (Figs. 1A and 2 and fig. S9). The P.1 sequences formed a single well-supported group (posterior probability=1.00) that clustered most closely with B.1.1.28 sequences from Manaus (“AM” in Fig. 2), suggesting P.1 emerged there. The earliest P.1 samples were detected in Manaus (34). The first known travel-related cases were detected in Japan (28) and São Paulo (table S3) and were both linked to travel from Manaus. Furthermore, the local clock model statistically confirms a higher evolutionary rate for the branch immediately ancestral to lineage P.1 compared with lineage B.1.1.28 as a whole (Bayes factor, BF=6.04).

Our data indicates multiple introductions of the P.1 lineage from Amazonas to Brazil’s south-eastern states (Fig. 2). We also detected seven small well-supported clusters of P.2 sequences from Amazonas (2–6 sequences, posterior probability=1.00). Virus exchange between Amazonas state and the urban metropolises in southeast Brazil largely follow patterns of national air travel mobility (Fig. 1D and fig. S10).

Infection with P.1 and sample viral loads

We analyzed all SARS-CoV-2 RT-qPCR positive results from a laboratory providing testing in Manaus since May 2020 (Fig. 1A and data file S1) with the aim of exploring trends in sample RT-qPCR cycle threshold (Ct) values, which are inversely related to sample virus loads and transmissibility (35). By focusing on data from a single laboratory, we reduce instrument and process variation that can affect Ct measurements.

We analyzed a set of RT-qPCR positive cases for which virus genome sequencing and lineage classification had been undertaken ($n = 147$). Using a logistic function (Fig. 3A) we find that the fraction of samples classified as P.1 increased from 0% to 87% in around 7 weeks (table S4), quantifying the trend shown in Fig. 1C. We found a small but statistically significant association between P.1 infection and lower Ct values, for both the E gene (lognormal regression, $p = 0.029$,

$n = 128$ samples, 65 of which were P.1) and N gene ($p = 0.01$, $n = 129$, 65 of which were P.1), with Ct values lowered by 1.43 (0.17–2.60 95% CI) and 1.91 (0.49–3.23) cycles in the P.1 lineage on average, respectively (Fig. 3B).

Using a larger sample of 942 Ct values (including an additional 795 samples for which no lineage information was available) we investigated Ct values across three time periods characterised by increasing P.1 relative abundance. Average Ct-values for both the E and N genes decline through time, as both case numbers and the fraction of P.1 infections increased, with Ct values significantly lower in period 3 compared to period 1 (Fig. 3C; E gene $p = 0.12$ and $p < 0.001$ for comparison of time periods 2 and 3 to period 1; N gene $p = 0.14$ and $p < 0.001$, respectively). Analyses of Ct values for samples from a different lab, also based in Manaus, showed similarly significant declines between the first and third time-periods defined here ($p < 0.0001$ for both E and N genes) (fig. S11 and data file S3).

However, population-level Ct distributions are sensitive to changes in the average time since infection when samples are taken, such that median Ct values can decrease during epidemic growth periods and increase during epidemic decline (36). To account for this effect, we assessed the association between P.1 infection and Ct levels while controlling for the delay between symptom onset and sample collection. Statistical significance was lost for both data sets (E gene $p = 0.15$, $n = 42$, 22 of which were P.1; N gene $p = 0.12$, $n = 42$, 22 of which were P.1). Owing to this confounding factor we cannot distinguish if P.1 infection is associated with increased viral loads (37) or a longer duration of infection (38).

Mathematical modelling of lineage P.1 epidemiological characteristics

We next explored epidemiological scenarios that might explain the recent resurgence of transmission in Manaus (39). To do this, we extend a semi-mechanistic Bayesian model of SARS-CoV-2 transmissibility and mortality (40–42) to include two categories of virus (“P.1” and “non-P.1”) and to account for infection severity, transmissibility and propensity for re-infection to vary between the categories. It also integrates information on the timing of P.1 emergence in Manaus using our molecular clock results (Fig. 2). The model explicitly incorporates waning of immune protection following infection, parameterized based on dynamics observed in recent studies (16, 43), to explore the competing hypothesis that waning of prior immunity might explain the observed resurgence (42). We use the model to evaluate the statistical support that P.1 possesses altered epidemiological characteristics compared to local non-P.1 lineages. Epidemiological model details and sensitivity analyses (tables S5 to S10) can be found in Supplementary Materials. The model is fitted to both COVID-19 mortality data (with a correction for systematic

reporting delays (44, 45) and to the estimated increase through time in the proportion of infections due to P.1 derived from genomic data (table S4). We assume within-category immunity wanes over time (50% wane within a year, though sensitivity analyses varying the rapidity of waning are presented in table S7) and that cross-immunity (the degree to which previous infection with a virus belonging to one category protects against subsequent infection with the other) is symmetric between categories.

Our results suggest the epidemiological characteristics of P.1 are different to those of previously circulating local SARS-CoV-2 lineages, but also highlight substantial uncertainty in the extent and nature of this difference. Plausible values of transmissibility and cross-immunity exist in a limited area but are correlated (Fig. 4A, with the extent of immune evasion defined as 1 minus the inferred cross-immunity). This is expected, because in the model a higher degree of cross-immunity means that greater transmissibility of P.1 is required to generate a second epidemic. Within this plausible region of parameter space, P.1 can be between 1.7–2.4 (50% BCI, 2.0 median, with a 99% posterior probability of being >1) times more transmissible than local non-P.1 lineages, and can evade 21–46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54–79% (50% BCI, 68% median) cross-immunity (Fig. 4A). The joint-posterior distribution is inconsistent with a combination of highly increased transmissibility and low cross-immunity, and conversely, also with near-complete cross-immunity but only a small increase in transmissibility (Fig. 4A). Moreover, our results further show that natural immunity waning alone is unlikely to explain the observed dynamics in Manaus, with support for P.1 possessing altered epidemiological characteristics robust to a range of values assumed for the date of the lineage's emergence and the rate of natural immunity waning (tables S5 and S7). We caution that these results are not generalisable to other settings; more detailed and direct data are needed to identify the exact degree and nature of the changes to the epidemiological characteristics of P.1 compared with previously circulating lineages.

We estimate that infections are 1.2–1.9 (50% BCI, median 1.5, 90% posterior probability of being >1) times more likely to result in mortality in the period following the emergence of P.1, compared to before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity (Fig. 4B). More broadly, the recent epidemic in Manaus has strained the city's healthcare system leading to inadequate access to medical care (46). We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus healthcare system, or both. Detailed clinical investigations of

P.1 infections are needed. We note that our model makes the assumption of a homogeneously mixed population, and therefore ignores heterogeneities in contact patterns (see for example fig. S13 for differences in private versus public hospitals). This is an important area for future research. The model fits observed time series data from Manaus on COVID-19 mortality (Fig. 4C), the relative frequency of P.1 infections (Fig. 4D) and also captures previously estimated trends in cumulative seropositivity in the city (Fig. 4E). We estimate the reproduction number (R_t) on 07 Feb 2021 to be 0.1 (median, 50% BCI: 0.04–0.2) for non-P.1 and 0.5 (median, 50% BCI: 0.4–0.6) for P.1 (Fig. 4F).

Characterisation and adaptation of a constellation of spike protein mutations

Lineage P.1 contains 10 lineage-defining amino acid mutations in the virus spike protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I) compared with its immediate ancestor (B.1.1.28). In addition to the possible increase in the rate of molecular evolution during the emergence of P.1, we found using molecular selection analyses (47), evidence that eight of these 10 mutations are under diversifying positive selection (table S1 and fig. S14).

Three key mutations present in P.1, N501Y, K417T and E484K, are in the spike protein RBD. The former two interact with human angiotensin-converting enzyme 2 (hACE2) (11), while E484K is located in a loop region outside the direct hACE2 interface (fig. S14). Notably, the same three residues are mutated with the B.1.351 variant of concern, and N501Y is also present in the B.1.1.7 lineage. The independent emergence of the same constellation of mutations in geographically distinct lineages indicates a process of convergent molecular adaptation. Similar to SARS-CoV-1 (48–50), mutations in the RBD may increase affinity of the virus for host ACE2 and consequently influence host cell entry and virus transmission. Recent molecular analysis of B.1.351 (51) indicates that the three P.1 RBD mutations may similarly enhance hACE2 engagement, providing a plausible hypothesis for an increase in transmissibility of the P.1 lineage. Moreover, E484K is associated with reduced antibody neutralisation (6, 9, 52, 53). RBD-presented epitopes account for ~90% of the neutralising activity of sera from individuals previously infected with SARS-CoV-2 (54), thus tighter binding of P.1 viruses to hACE2 may further reduce the effectiveness of neutralizing antibodies.

Conclusion

We show that P.1 most likely emerged in Manaus in mid-November, where high attack rates have been previously reported. High rates of mutation accumulation over short time periods have been reported in chronically infected or immunocompromised patients (13). Given a sustained generalised

epidemic in Manaus we believe this is a potential scenario for P.1 emergence. Genomic surveillance and early data sharing by teams worldwide has led to the rapid detection and characterisation of SARS-CoV-2 and new variants of concern (25), yet such surveillance is still limited in many settings. The P.1 lineage is spreading rapidly across Brazil (55), and this lineage has now been detected in >36 countries (56). But existing virus genome sampling strategies are often inadequate for determining the true extent of VOCs in Brazil, and more detailed data are needed to address the impact of different epidemiological and evolutionary processes in their emergence. Sustainable genomic surveillance efforts to track variant frequency [e.g., (57–59)] coupled with analytical tools to quantify lineage dynamics [e.g., (60, 61)] and anonymized epidemiological surveillance data (62, 63) could enable enhanced real-time surveillance of variants of concern worldwide. Studies to evaluate real-world vaccine efficacy in response to P.1 are urgently needed. We note that neutralisation titers represent only one component of the elicited response to vaccines, and that minimal reduction of neutralisation titers relative to earlier circulating strains is not uncommon. Until an equitable allocation and access to effective vaccines is available to all, non-pharmaceutical interventions should continue to play an important role in reducing the emergence of new variants.

REFERENCES AND NOTES

1. P. C. Hallal, F. P. Hartwig, B. L. Horta, M. F. Silveira, C. J. Struchiner, L. P. Vdaletti, N. A. Neumann, L. C. Pellanda, O. A. Dellagostin, M. N. Burattini, G. D. Victora, A. M. B. Menezes, F. C. Barros, A. J. D. Barros, C. G. Victora, SARS-CoV-2 antibody prevalence in Brazil: Results from two successive nationwide serological household surveys. *Lancet Glob. Health* **8**, e1390–e1398 (2020). [doi:10.1016/S2214-109X\(20\)30387-9](https://doi.org/10.1016/S2214-109X(20)30387-9) [Medline](#)
2. L. F. Buss, C. A. Prete Jr., C. M. M. Abraham, A. Mendrone Jr., T. Salomon, C. de Almeida-Neto, R. F. O. França, M. C. Belotti, M. P. S. S. Carvalho, A. G. Costa, M. A. E. Crispim, S. C. Ferreira, N. A. Fraiji, S. Gurzenda, C. Whittaker, L. T. Kamaura, P. L. Takecian, P. da Silva Peixoto, M. K. Oikawa, A. S. Nishiya, V. Rocha, N. A. Salles, A. A. de Souza Santos, M. A. da Silva, B. Custer, K. V. Parag, M. Barral-Netto, M. U. G. Kraemer, R. H. M. Pereira, O. G. Pybus, M. P. Busch, M. C. Castro, C. Dye, V. H. Nascimento, N. R. Faria, E. C. Sabino, Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science* **371**, 288–292 (2021). [doi:10.1126/science.abe9728](https://doi.org/10.1126/science.abe9728) [Medline](#)
3. C. Álvarez-Antonio, G. Meza-Sánchez, C. Calampa, W. Casanova, C. Carey, F. Alava, H. Rodríguez-Ferrucci, A. M. Quispe, Seroprevalence of Anti-SARS-CoV-2 Antibodies in Iquitos, Loreto, Peru. *medRxiv* 21249913 [Preprint] 20 January 2021. [doi:10.1101/2021.01.17.21249913](https://doi.org/10.1101/2021.01.17.21249913)
4. M. Mercado, M. Ospina, Instituto Nacional de Salud, “Seroprevalencia de SARS-CoV-2 durante la epidemia en Colombia: estudio país” (2020); www.ins.gov.co/BibliotecaDigital/Seroprevalencia-estudio-colombia.pdf
5. Fundação de Vigilância em Saúde do Amazonas, “Perfil clínico e demográfico dos casos de Covid-19 no estado do Amazonas: uma análise comparativa entre 2020 e 2021,” No. 17 (2021); www.fvs.am.gov.br/media/publicacao/boletim_covid_17.pdf
6. A. J. Greaney, A. N. Loes, K. H. D. Crawford, T. N. Starr, K. D. Malone, H. Y. Chu, J. D. Bloom, Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* **29**, 463–476.e6 (2021). [doi:10.1016/j.chom.2021.02.003](https://doi.org/10.1016/j.chom.2021.02.003) [Medline](#)
7. T. N. Starr, A. J. Greaney, S. K. Hilton, D. Ellis, K. H. D. Crawford, A. S. Dings, M. J. Navarro, J. E. Bowen, M. A. Tortorici, A. C. Walls, N. P. King, D. Veer, J. D. Bloom, Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. *Cell* **182**, 1295–1310.e20 (2020). [doi:10.1016/j.cell.2020.08.012](https://doi.org/10.1016/j.cell.2020.08.012) [Medline](#)
8. M. A. Suchard, R. E. Weiss, J. S. Sinsheimer, Testing a molecular clock without an outgroup: Derivations of induced priors on branch-length restrictions in a Bayesian framework. *Syst. Biol.* **52**, 48–54 (2003). [doi:10.1080/10635150390132713](https://doi.org/10.1080/10635150390132713) [Medline](#)
9. Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Fink, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West, K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J. Dizon, C. Unson-O'Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J. Bjorkman, R. Casellas, T. Hatzioannou, P. D. Bieniasz, M. C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* (2021). [doi:10.1038/s41586-021-03324-6](https://doi.org/10.1038/s41586-021-03324-6) [Medline](#)
10. Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, L. Luchsinger, C. D. Hillyer, M. Caskey, D. F. Robbiani, C. M. Rice, M. C. Nussenzweig, T. Hatzioannou, P. D. Bieniasz, Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *eLife* **9**, e61312 (2020). [doi:10.7554/elife.61312](https://doi.org/10.7554/elife.61312) [Medline](#)
11. J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, X. Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **581**, 215–220 (2020). [doi:10.1038/s41586-020-2180-5](https://doi.org/10.1038/s41586-020-2180-5) [Medline](#)
12. H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S. Pillay, E. J. San, N. Msomi, K. Misana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T. Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G. Marais, N. Y. Hsiao, S. Korsman, M.-A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell, J. Lourenço, L. C. J. Alcantara, S. L. Kosakovsky Pond, S. Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C. Williamson, T. de Oliveira, Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* (2021). [doi:10.1038/s41586-021-03402-9](https://doi.org/10.1038/s41586-021-03402-9) [Medline](#)
13. A. Rambaut, N. Loman, O. Pybus, W. Barclay, J. Barrett, Carabelli, A., Connor, T., Peacock, T., Robertson, D. L., Volz, E., on behalf of COVID-19 Genomics Consortium UK (CCoG-UK), “Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations” (2020); <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>
14. SAMRC Report on Weekly Deaths in South Africa (available at <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa?bc=254>). (2021).
15. N. L. Washington et al., Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *medRxiv* 21251159 [Preprint] 7 February 2021. [doi:10.1101/2021.02.06.21251159](https://doi.org/10.1101/2021.02.06.21251159)
16. C. H. Hansen, D. Michlmayr, S. M. Gubbels, K. Mølbak, S. Ethelberg, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study. *Lancet* **397**, 1204–1212 (2021). [doi:10.1016/S0140-6736\(21\)00575-4](https://doi.org/10.1016/S0140-6736(21)00575-4) [Medline](#)
17. E. Volz, S. Mishra, M. Chand, J. C. Barrett, R. Johnson, L. Geidelberg, W. R. Hinsley, D. J. Laydon, G. Dabrera, Á. O’Toole, R. Amato, M. Ragonnet-Cronin, I. Harrison, B. Jackson, C. V. Ariani, O. Boyd, N. J. Loman, J. T. McCrone, S. Gonçalves, D. Jorgensen, R. Myers, V. Hill, D. K. Jackson, K. Gaythorpe, N. Groves, J. Sillitoe, D. P. Kwiatkowski, S. Flaxman, O. Ratmann, S. Bhatt, S. Hopkins, A. Gandy, A. Rambaut, N. M. Ferguson, COVID-19 Genomics UK (COG-UK) consortium, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* (2021). [doi:10.1038/s41586-021-03470-x](https://doi.org/10.1038/s41586-021-03470-x) [Medline](#)
18. D. D. S. Candido, A. Watts, L. Abade, M. U. G. Kraemer, O. G. Pybus, J. Croda, W. de Oliveira, K. Khan, E. C. Sabino, N. R. Faria, Routes for COVID-19 importation in Brazil. *J. Travel Med.* **27**, taaa042 (2020). [doi:10.1093/jtm/taaa042](https://doi.org/10.1093/jtm/taaa042) [Medline](#)

19. D. S. Candido, I. M. Claro, J. G. de Jesus, W. M. Souza, F. R. R. Moreira, S. Dellicour, T. A. Mellan, L. du Plessis, R. H. M. Pereira, F. C. S. Sales, E. R. Manuli, J. Thézé, L. Almeida, M. T. Menezes, C. M. Voloch, M. J. Fumagalli, T. M. Coletti, C. A. M. da Silva, M. S. Ramundo, M. R. Amorim, H. H. Hoeltgebaum, S. Mishra, M. S. Gill, L. M. Carvalho, L. F. Buss, C. A. Prete Jr., J. Ashworth, H. I. Nakaya, P. S. Peixoto, O. J. Brady, S. M. Nicholls, A. Tanuri, Á. D. Rossi, C. K. V. Braga, A. L. Gerber, A. P. de C. Guimarães, N. Gaburo Jr., C. S. Alencar, A. C. S. Ferreira, C. X. Lima, J. E. Levi, C. Granato, G. M. Ferreira, R. S. Francisco Jr., F. Granja, M. T. Garcia, M. L. Moretti, M. W. Perroud Jr., T. M. P. P. Castañeiras, C. S. Lazari, S. C. Hill, A. A. de Souza Santos, C. L. Simeoni, J. Forato, A. C. Sposito, A. Z. Schreiber, M. N. N. Santos, C. Z. de Sá, R. P. Souza, L. C. Resende-Moreira, M. M. Teixeira, J. Hubner, P. A. F. Leme, R. G. Moreira, M. L. Nogueira, N. M. Ferguson, S. F. Costa, J. L. Proenca-Modena, A. T. R. Vasconcelos, S. Bhatt, P. Lemey, C.-H. Wu, A. Rambaut, N. J. Loman, R. S. Aguiar, O. G. Pybus, E. C. Sabino, N. R. Faria; Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE) Genomic Network, Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science* **369**, 1255–1260 (2020). [doi:10.1126/science.abd2161](https://doi.org/10.1126/science.abd2161) [Medline](#)
20. W. M. de Souza, L. F. Buss, D. D. S. Candido, J.-P. Carrera, S. Li, A. E. Zarebski, R. H. M. Pereira, C. A. Prete Jr., A. A. de Souza-Santos, K. V. Parag, M. C. T. D. Belotti, M. F. Vincenti-Gonzalez, J. Messina, F. C. da Silva Sales, P. D. S. Andrade, V. H. Nascimento, F. Ghilardi, L. Abade, B. Gutierrez, M. U. G. Kraemer, C. K. V. Braga, R. S. Aguiar, N. Alexander, P. Mayaud, O. J. Brady, I. Marcilio, N. Gouveia, G. Li, A. Tami, S. B. de Oliveira, V. B. G. Porto, F. Ganem, W. A. F. de Almeida, F. F. S. T. Fantinato, E. M. Macário, W. K. de Oliveira, M. L. Nogueira, O. G. Pybus, C.-H. Wu, J. Croda, E. C. Sabino, N. R. Faria, Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. *Nat. Hum. Behav.* **4**, 856–865 (2020). [doi:10.1038/s41562-020-0928-4](https://doi.org/10.1038/s41562-020-0928-4) [Medline](#)
21. J. G. Jesus, C. Sacchi, D. D. S. Candido, I. M. Claro, F. C. S. Sales, E. R. Manuli, D. B. B. D. Silva, T. M. Paiva, M. A. B. Pinho, K. C. O. Santos, S. C. Hill, R. S. Aguiar, F. Romero, F. C. P. D. Santos, C. R. Gonçalves, M. D. C. Timenetsky, J. Quick, J. H. R. Croda, W. Oliveira, A. Rambaut, O. G. Pybus, N. J. Loman, E. C. Sabino, N. R. Faria, Importation and early local transmission of COVID-19 in Brazil, 2020. *Rev. Inst. Med. Trop. São Paulo* **62**, e30 (2020). [doi:10.1590/s1678-9946202062030](https://doi.org/10.1590/s1678-9946202062030) [Medline](#)
22. I. M. Claro, F. C. da Silva Sales, M. S. Ramundo, D. S. Candido, C. A. M. Silva, J. G. de Jesus, E. R. Manuli, C. M. de Oliveira, L. Scarpelli, G. Campana, O. G. Pybus, E. C. Sabino, N. R. Faria, J. E. Levi, Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020. *Emerg. Infect. Dis.* **27**, 970–972 (2021). [doi:10.3201/eid2703.210038](https://doi.org/10.3201/eid2703.210038) [Medline](#)
23. V. A. D. Nascimento, A. L. G. Corado, F. O. D. Nascimento, Á. K. A. D. Costa, D. C. G. Duarte, S. L. B. Luz, L. M. F. Gonçalves, M. S. Jesus, C. F. D. Costa, E. Delatorre, F. G. Naveca, Genomic and phylogenetic characterisation of an imported case of SARS-CoV-2 in Amazonas State, Brazil. *Mem. Inst. Oswaldo Cruz* **115**, e200310 (2020). [doi:10.1590/0074-02760200310](https://doi.org/10.1590/0074-02760200310) [Medline](#)
24. J. R. Tyson, P. James, D. Stoddart, N. Sparks, A. Wickenhagen, G. Hall, J. H. Choi, H. Lapointe, K. Kamelian, A. D. Smith, N. Prystajek, I. Goodfellow, S. J. Wilson, R. Harrigan, T. P. Snutch, N. J. Loman, J. Quick, Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. *bioRxiv* 2020.09.04.283077 [doi:10.1101/2020.09.04.283077](https://doi.org/10.1101/2020.09.04.283077) (2020). [Medline](#)
25. World Health Organization, (2021). Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 8 January 2021. World Health Organization (2021); <https://apps.who.int/iris/handle/10665/338480>
26. A. Rambaut, E. C. Holmes, Á. O'Toole, V. Hill, J. T. McCrone, C. Ruis, L. du Plessis, O. G. Pybus, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat. Microbiol.* **5**, 1403–1407 (2020). [doi:10.1038/s41564-020-0770-5](https://doi.org/10.1038/s41564-020-0770-5) [Medline](#)
27. N. R. Faria, I. M. Claro, D. Candido, L. A. M. Franco, P. S. Andrade, T. M. Coletti, C. A. M. Silva, F. C. Sales, E. R. Manuli, R. S. Aguiar, N. Gaburo, C. C. Camilo, N. A. Fraiji, M. A. E. Crispim, M. P. S. S. Carvalho, A. Rambaut, N. Loman, O. G. Pybus, E. C. Sabino, on behalf of CADDE Genomic Network, “Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings” (2021); <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manauas-preliminary-findings/586>
28. T. Fujino, H. Nomoto, S. Kutsuna, M. Ujiie, T. Suzuki, R. Sato, T. Fujimoto, M. Kuroda, T. Wakita, N. Ohmagari, Novel SARS-CoV-2 variant in travelers from Brazil to Japan. *Emerg. Infect. Dis.* **27**, (2021). [doi:10.3201/eid2704.210138](https://doi.org/10.3201/eid2704.210138) [Medline](#)
29. A. Rambaut, T. T. Lam, L. Max Carvalho, O. G. Pybus, Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* **2**, vew007 (2016). [doi:10.1093/ve/vew007](https://doi.org/10.1093/ve/vew007) [Medline](#)
30. B. Choi, M. C. Choudhary, J. Regan, J. A. Sparks, R. F. Padera, X. Qiu, I. H. Solomon, H.-H. Kuo, J. Boucay, K. Bowman, U. D. Adhikari, M. L. Winkler, A. A. Mueller, T. Y.-T. Hsu, M. Desjardins, L. R. Baden, B. T. Chan, B. D. Walker, M. Lichterfeld, M. Brigl, D. S. Kwon, S. Kanjilal, E. T. Richardson, A. H. Jonsson, G. Alter, A. K. Barczak, W. P. Hanage, X. G. Yu, G. D. Gaiha, M. S. Seaman, M. Cernadas, J. Z. Li, Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N. Engl. J. Med.* **383**, 2291–2293 (2020). [doi:10.1056/NEJMc2031364](https://doi.org/10.1056/NEJMc2031364) [Medline](#)
31. V. A. Avanzato, M. J. Matson, S. N. Seifert, R. Pryce, B. N. Williamson, S. L. Anzick, K. Barbian, S. D. Judson, E. R. Fischer, C. Martens, T. A. Bowden, E. de Wit, F. X. Riedo, V. J. Munster, Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. *Cell* **183**, 1901–1912.e9 (2020). [doi:10.1016/j.cell.2020.10.049](https://doi.org/10.1016/j.cell.2020.10.049) [Medline](#)
32. A. J. Drummond, M. A. Suchard, Bayesian random local clocks, or one rate to rule them all. *BMC Biol.* **8**, 114 (2010). [doi:10.1186/1741-7007-8-114](https://doi.org/10.1186/1741-7007-8-114) [Medline](#)
33. M. S. Gill, P. Lemey, N. R. Faria, A. Rambaut, B. Shapiro, M. A. Suchard, Improving Bayesian population dynamics inference: A coalescent-based model for multiple loci. *Mol. Biol. Evol.* **30**, 713–724 (2013). [doi:10.1093/molbev/mss265](https://doi.org/10.1093/molbev/mss265) [Medline](#)
34. F. N. Naveca et al., COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1. *Nat. Portfolio* 10.21203/rs.3.rs-275494/v1 (2021).
35. M. Marks, P. Millat-Martinez, D. Ouchi, C. H. Roberts, A. Alemany, M. Corbacho-Monné, M. Ubals, A. Tobias, C. Tebé, E. Ballana, Q. Bassat, B. Baro, M. Vall-Mayans, C. G-Beiras, N. Prat, J. Ara, B. Clotet, O. Mitjà, Transmission of COVID-19 in 282 clusters in Catalonia, Spain: A cohort study. *Lancet Infect. Dis.* S1473-3099(20)30985-3 (2021). [doi:10.1016/S1473-3099\(20\)30985-3](https://doi.org/10.1016/S1473-3099(20)30985-3) [Medline](#)
36. J. A. Hay, Kennedy-Shaffer, L., Kanjilal, S., Lipsitch, M., Mina, M. J. Estimating epidemiologic dynamics from single cross-sectional viral load distributions. *medRxiv* 20204222 [Preprint] 13 February 2021). [doi:10.1101/2020.10.08.20204222](https://doi.org/10.1101/2020.10.08.20204222)
37. M. Kidd, A. Richter, A. Best, N. Cumley, J. Mirza, B. Percival, M. Mayhew, O. Megram, F. Ashford, T. White, E. Moles-Garcia, L. Crawford, A. Bosworth, S. F. Atabani, T. Plant, A. McNally, S-variant SARS-CoV-2 lineage B.1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. *J. Infect. Dis.* jia082 (2021). [doi:10.1093/infdis/jia082](https://doi.org/10.1093/infdis/jia082) [Medline](#)
38. K. Stephen et al., Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2 (2021); <https://nrs.harvard.edu/URN:3:HUL.INSTREPOS:37366884>
39. E. C. Sabino, L. F. Buss, M. P. S. Carvalho, C. A. Prete Jr., M. A. E. Crispim, N. A. Fraiji, R. H. M. Pereira, K. V. Parag, P. da Silva Peixoto, M. U. G. Kraemer, M. K. Oikawa, T. Salomon, Z. M. Cucunuba, M. C. Castro, A. A. de Souza Santos, V. H. Nascimento, H. S. Pereira, N. M. Ferguson, O. G. Pybus, A. Kucharski, M. P. Busch, C. Dye, N. R. Faria, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet* **397**, 452–455 (2021). [doi:10.1016/S0140-6736\(21\)00183-5](https://doi.org/10.1016/S0140-6736(21)00183-5) [Medline](#)
40. H. J. T. Unwin, S. Mishra, V. C. Bradley, A. Gandy, T. A. Mellan, H. Coupland, J. Ish-Horowicz, M. A. C. Vollmer, C. Whittaker, S. L. Filippi, X. Xi, M. Monod, O. Ratmann, M. Hutchinson, F. Valka, H. Zhu, I. Hawryluk, P. Milton, K. E. C. Ainslie, M. Baguelin, A. Boonyasiri, N. F. Brazeau, L. Cattarino, Z. Cucunuba, G. Cuomo-Dannenburg, I. Dorigatti, O. D. Eales, J. W. Eaton, S. L. van Elsland, R. G. FitzJohn, K. A. M. Gaythorpe, W. Green, W. Hinsley, B. Jeffrey, E. Knock, D. J. Laydon, J. Lees, G. Nedjati-Gilani, P. Nouvellet, L. Okell, K. V. Parag, I. Siveroni, H. A. Thompson, P. Walker, C. E. Walters, O. J. Watson, L. K. Whittles, A. C. Ghani, N. M. Ferguson, S. Riley, C. A. Donnelly, S. Bhatt, S. Flaxman, State-level tracking of COVID-19 in the United States. *Nat. Commun.* **11**, 6189 (2020). [doi:10.1038/s41467-020-19652-6](https://doi.org/10.1038/s41467-020-19652-6) [Medline](#)

41. S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittaker, H. Zhu, T. Berah, J. W. Eaton, M. Monod, A. C. Ghani, C. A. Donnelly, S. Riley, M. A. C. Vollmer, N. M. Ferguson, L. C. Okell, S. Bhatt; Imperial College COVID-19 Response Team, Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* **584**, 257–261 (2020). [doi:10.1038/s41586-020-2405-7](https://doi.org/10.1038/s41586-020-2405-7) [Medline](#)
42. James Scott, Axel Gandy, Swapnil Mishra, Juliette Unwin, Seth Flaxman, Samir Bhatt, Epidemia - Modeling of epidemics using hierarchical Bayesian models; <https://imperialcollegelondon.github.io/epidemia/index.html>.
43. V. Hall *et al.*, Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. *bioRxiv* 21249642 [Preprint] 15 January 2021. [doi:10.1101/2021.01.13.21249642](https://doi.org/10.1101/2021.01.13.21249642)
44. S. F. McGough, M. A. Johansson, M. Lipsitch, N. A. Menzies, Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking. *PLOS Comput. Biol.* **16**, e1007735 (2020). [doi:10.1371/journal.pcbi.1007735](https://doi.org/10.1371/journal.pcbi.1007735) [Medline](#)
45. I. Hawryluk, H. Hoeltgebaum, S. Mishra, X. Miskouridou, R. P. Schnekenberg, C. Whittaker, M. Vollmer, S. Flaxman, T. A. Mellaan, Gaussian Process Nowcasting: Application to COVID-19 Mortality Reporting. *arXiv arXiv:2102.11249*, (2021).
46. Agencia Brasil, Covid-19: Amazonas já transferiu 424 pacientes para outros estados (2021); <https://agenciabrasil.ebc.com.br/saude/noticia/2021-02/covid-19-amazonas-ja-transferiu-424-pacientes-para-outros-estados>.
47. S. L. Pond, S. D. Frost, S. V. Muse, HyPhy: Hypothesis testing using phylogenies. *Bioinformatics* **21**, 676–679 (2005). [doi:10.1093/bioinformatics/bti079](https://doi.org/10.1093/bioinformatics/bti079) [Medline](#)
48. X. X. Qu, P. Hao, X.-J. Song, S.-M. Jiang, Y.-X. Liu, P.-G. Wang, X. Rao, H.-D. Song, S.-Y. Wang, Y. Zuo, A.-H. Zheng, M. Luo, H.-L. Wang, F. Deng, H.-Z. Wang, Z.-H. Hu, M.-X. Ding, G.-P. Zhao, H.-K. Deng, Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. *J. Biol. Chem.* **280**, 29588–29595 (2005). [doi:10.1074/jbc.M500662200](https://doi.org/10.1074/jbc.M500662200) [Medline](#)
49. H. D. Song, C.-C. Tu, G.-W. Zhang, S.-Y. Wang, K. Zheng, L.-C. Lei, Q.-X. Chen, Y.-W. Gao, H.-Q. Zhou, H. Xiang, H.-J. Zheng, S.-W. W. Chern, F. Cheng, C.-M. Pan, H. Xuan, S.-J. Chen, H.-M. Luo, D.-H. Zhou, Y.-F. Liu, J.-F. He, P.-Z. Qin, L.-H. Li, Y.-Q. Ren, W.-J. Liang, Y.-D. Yu, L. Anderson, M. Wang, R.-H. Xu, X.-W. Wu, H.-Y. Zheng, J.-D. Chen, G. Liang, Y. Gao, M. Liao, L. Fang, L.-Y. Jiang, H. Li, F. Chen, B. Di, L.-J. He, J.-Y. Lin, S. Tong, X. Kong, L. Du, P. Hao, H. Tang, A. Bernini, X.-J. Yu, O. Spiga, Z.-M. Guo, H.-Y. Pan, W.-Z. He, J.-C. Manuguerra, A. Fontanet, A. Danchin, N. Niccolai, Y.-X. Li, C.-I. Wu, G.-P. Zhao, Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2430–2435 (2005). [doi:10.1073/pnas.0409608102](https://doi.org/10.1073/pnas.0409608102) [Medline](#)
50. W. Li, C. Zhang, J. Sui, J. H. Kuhn, M. J. Moore, S. Luo, S.-K. Wong, I.-C. Huang, K. Xu, N. Vasileva, A. Murakami, Y. He, W. A. Marasco, Y. Guan, H. Choe, M. Farzan, Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J.* **24**, 1634–1643 (2005). [doi:10.1038/sj.emboj.7600640](https://doi.org/10.1038/sj.emboj.7600640) [Medline](#)
51. D. Zhou, W. Dejnirattisai, P. Supasa, C. Liu, A. J. Mentzer, H. M. Ginn, Y. Zhao, H. M. E. Duyvesteyn, A. Tuekprakhon, R. Ntulai, B. Wang, G. C. Paesen, C. Lopez-Camacho, J. Slon-Campos, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T. S. Walter, D. Skelly, S. F. Lumley, C. Dold, R. Levin, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, S. Belij-Rammerstorfer, S. Gilbert, W. James, M. W. Carroll, P. Klennerman, E. Barnes, S. J. Dunachie, E. E. Fry, J. Mongkolsapaya, J. Ren, D. I. Stuart, G. R. Screaton, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* **S0092-8674(21)00226-9** (2021). [doi:10.1016/j.cell.2021.02.037](https://doi.org/10.1016/j.cell.2021.02.037) [Medline](#)
52. C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuisen, B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van der Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. Meiring, A. von Gottberg, C. Cohen, L. Morris, J. N. Bhiman, P. L. Moore, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat. Med.* (2021). [doi:10.1038/s41591-021-01285-x](https://doi.org/10.1038/s41591-021-01285-x) [Medline](#)
53. S. Cele, I. Gazy, L. Jackson, S.-H. Hwa, H. Tegally, G. Lustig, J. Giandhari, S. Pillay, E. Wilkinson, Y. Naidoo, F. Karim, Y. Ganga, K. Khan, M. Bernstein, A. B. Balazs, B. I. Gosnell, W. Hanekom, M. S. Moosa, R. J. Lessells, T. de Oliveira, A. Sigal; NGS-SA; COMMIT-KZN Team, Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. *Nature* (2021). [doi:10.1038/s41586-021-03471-w](https://doi.org/10.1038/s41586-021-03471-w) [Medline](#)
54. L. Piccoli, Y.-J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C. Silacci-Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A. Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J. C. Nix, F. Mele, S. Jovic, B. F. Rodriguez, S. V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A. F. Pellanda, M. Biggiogero, M. Tarkowski, M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, H. W. Virgin, A. Lanzavecchia, D. Corti, D. Veessler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024–1042.e21 (2020). [doi:10.1016/j.cell.2020.09.037](https://doi.org/10.1016/j.cell.2020.09.037) [Medline](#)
55. A. F. Z. Martins, A. P. Zavascki, P. L. Wink, F. C. Z. Volpato, F. L. Monteiro, C. Rosset, F. De-Paris, Á. K. Ramos, A. L. Barth, Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. *Euro Surveill.* **26**, 2100276 (2021). [doi:10.2807/1560-7917.ES.2021.26.12.2100276](https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100276) [Medline](#)
56. A. O'Toole, V. Hill, O. G. Pybus, A. Watts, I. I. Bogoch, K. Khan, J. P. Messina, The COVID-19 Genomics UK (COG-UK) consortium, *et al.*, “Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2” (2021) ; <https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592>.
57. TESSy. The European Surveillance System (TESSy) (2015); www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessey.
58. COG-UK, COVID-19 Genomics UK Consortium (2020); www.cogconsortium.uk.
59. SPHERES, SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance; (2020); www.cdc.gov/coronavirus/2019-ncov/covid-data/spheres.html.
60. L. du Plessis, J. T. McCrone, A. E. Zarebski, V. Hill, C. Ruis, B. Gutierrez, J. Raghwan, J. Ashworth, R. Colquhoun, T. R. Connor, N. R. Faria, B. Jackson, N. J. Loman, Á. O'Toole, S. M. Nicholls, K. V. Parag, E. Scher, T. I. Vasylyeva, E. M. Volz, A. Watts, I. I. Bogoch, K. Khan, D. M. Aanensen, M. U. G. Kraemer, A. Rambaut, O. G. Pybus; COVID-19 Genomics UK (COG-UK) Consortium, Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science* **371**, 708–712 (2021). [doi:10.1126/science.abb2946](https://doi.org/10.1126/science.abb2946) [Medline](#)
61. E. Volz, V. Hill, J. T. McCrone, A. Price, D. Jorgensen, Á. O'Toole, J. Southgate, R. Johnson, B. Jackson, F. F. Nascimento, S. M. Rey, S. M. Nicholls, R. M. Colquhoun, A. da Silva Filipe, J. Shepherd, D. J. Pascall, R. Shah, N. Jesudason, K. Li, R. Jarrett, N. Pacchiarini, M. Bull, L. Geidelberg, I. Siveroni, I. Goodfellow, N. J. Loman, O. G. Pybus, D. L. Robertson, E. C. Thomson, A. Rambaut, T. R. Connor, Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell* **184**, 64–75.e11 (2021). [doi:10.1016/j.cell.2020.11.020](https://doi.org/10.1016/j.cell.2020.11.020) [Medline](#)
62. B. Xu, M. U. G. Kraemer, Open COVID-19 Data Curation Group, Open access epidemiological data from the COVID-19 outbreak. *Lancet Infect. Dis.* **20**, 534 (2020). [doi:10.1016/S1473-3099\(20\)30119-5](https://doi.org/10.1016/S1473-3099(20)30119-5) [Medline](#)
63. Global.health (2021); <https://global.health>.
64. GitHub Repository; <https://github.com/CADDE-CENTRE>.
65. S., CADDE CENTRE, C. Whittaker, CADDE-CENTRE/Novel-SARS-CoV-2-P1-Lineage-in-Brazil: Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil (peer-review version out soon). Zenodo (2021); [doi:10.5281/zenodo.4676853](https://doi.org/10.5281/zenodo.4676853).
66. Fundação de Vigilância em Saúde do Amazonas, Amazonas, “Dados epidemiológicos e financeiros das ações de combate à COVID-19. Publicações (2021); www.fvs.am.gov.br/publicacoes.
67. SRAG 2020 - Banco de Dados de Síndrome Respiratória Aguda Grave - incluindo dados da COVID-19 - Open Data; <https://opendatasus.saude.gov.br/dataset/bd-srag-2020>.
68. Y. Shu, J. McCauley, GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill.* **22**, 30494 (2017). [doi:10.2807/1560-7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494) [Medline](#)
69. SRAG 2021 - Banco de Dados de Síndrome Respiratória Aguda Grave - incluindo dados da COVID-19 - Open Data; <https://opendatasus.saude.gov.br/dataset/bd-srag-2021>.

70. E. Farfour, P. Lesprit, B. Visseaux, T. Pascreau, E. Jolly, N. Houhou, L. Mazaux, M. Asso-Bonnet, M. Vasse: SARS-CoV-2 Foch Hospital study group. The Allplex 2019-nCoV (Seegene) assay: Which performances are for SARS-CoV-2 infection diagnosis? *Eur. J. Clin. Microbiol. Infect. Dis.* **39**, 1997–2000 (2020). [doi:10.1007/s10096-020-03930-8](https://doi.org/10.1007/s10096-020-03930-8) [Medline](#)
71. F. M. Liotti, G. Menchinelli, S. Marchetti, G. A. Morandotti, M. Sanguinetti, B. Posteraro, P. Cattani, Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples. *Eur. J. Clin. Microbiol. Infect. Dis.* **40**, 269–277 (2021). [doi:10.1007/s10096-020-04025-0](https://doi.org/10.1007/s10096-020-04025-0) [Medline](#)
72. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, R. Durbin; 1000 Genome Project Data Processing Subgroup, The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009). [doi:10.1093/bioinformatics/btp352](https://doi.org/10.1093/bioinformatics/btp352) [Medline](#)
73. I. Milne, M. Bayer, L. Cardle, P. Shaw, G. Stephen, F. Wright, D. Marshall, Tablet—Next generation sequence assembly visualization. *Bioinformatics* **26**, 401–402 (2010). [doi:10.1093/bioinformatics/btp666](https://doi.org/10.1093/bioinformatics/btp666) [Medline](#)
74. K. Katoh, D. M. Standley, MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013). [doi:10.1093/molbev/mst010](https://doi.org/10.1093/molbev/mst010) [Medline](#)
75. M. C. dos Santos, E. C. Sousa Jr., J. A. Ferreira, S. P. Silva, M. P. C. Souza, J. F. Cardoso, A. M. Silva, L. S. Barbagelata, W. D. Chagas Jr., J. L. Ferreira, E. M. A. Souza, P. L. A. Vilaca, J. C. S. Alves, M. C. Abreu, P. S. Lobo, F. S. Santos, A. P. Lima, C. M. Bragagnolo, L. S. Soares, P. S. M. Almeida, D. S. Oliveira, C. K. N. Amorim, I. B. Costa, D. M. Teixeira, E. T. Penha Jr., D. A. M. Bezerra, J. A. M. Siqueira, F. N. Tavares, F. B. Freitas, J. T. N. Rodrigues, J. Mazaro, A. S. Costa, M. S. P. Cavalcante, M. S. Silva, I. A. Silva, G. A. L. Borges, L. G. Lima, H. L. S. Ferreira, M. T. Livorati, A. L. Abreu, A. C. Medeiros, H. R. Resque, R. C. M. Sousa, G. M. R. Viana, Molecular epidemiology to understand the SARS-CoV-2 emergence in the Brazilian Amazon. *bioRxiv* 20184523 [Preprint] 7 September 2020). [doi:10.1101/2020.09.04.20184523](https://doi.org/10.1101/2020.09.04.20184523)
76. J. Xavier, M. Giovanetti, T. Adelino, V. Fonseca, A. V. Barbosa da Costa, A. A. Ribeiro, K. N. Felicio, C. G. Duarte, M. V. Ferreira Silva, Á. Salgado, M. T. Lima, R. de Jesus, A. Fabri, C. F. Soares Zoboli, T. G. Souza Santos, F. Iani, M. Ciccozzi, A. M. Bispo de Filippis, M. A. M. Teixeira de Siqueira, A. L. de Abreu, V. de Azevedo, D. B. Ramalho, C. F. Campelo de Albuquerque, T. de Oliveira, E. C. Holmes, J. Lourenço, L. C. Junior Alcantara, M. A. Assunção Oliveira, The ongoing COVID-19 epidemic in Minas Gerais, Brazil: Insights from epidemiological data and SARS-CoV-2 whole genome sequencing. *Emerg. Microbes Infect.* **9**, 1824–1834 (2020). [doi:10.1080/22221751.2020.1803146](https://doi.org/10.1080/22221751.2020.1803146) [Medline](#)
77. M. H. S. Paiva, D. R. D. Guedes, C. Docena, M. F. Bezerra, F. Z. Dezordi, L. C. Machado, L. Krokovsky, E. Helvecio, A. F. da Silva, L. R. S. Vasconcelos, A. M. Rezende, S. J. R. da Silva, K. G. D. S. Sales, B. S. L. F. de Sá, D. L. da Cruz, C. E. Cavalcanti, A. M. Neto, C. T. A. da Silva, R. P. G. Mendes, M. A. L. da Silva, T. Gräf, P. C. Resende, G. Bello, M. D. S. Barros, W. R. C. do Nascimento, R. M. L. Arcoverde, L. C. A. Bezerra, S. P. B. Filho, C. F. J. Ayres, G. L. Wallau, Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil. *Viruses* **12**, E1414 (2020). [doi:10.3390/v12121414](https://doi.org/10.3390/v12121414) [Medline](#)
78. J. D. Siqueira, L. R. Goes, B. M. Alves, P. S. de Carvalho, C. Cicala, J. Arthos, J. P. B. Viola, A. C. de Melo, M. A. Soares, SARS-CoV-2 genomic and quasispecies analyses in cancer patients reveal relaxed intrahost virus evolution. *bioRxiv* 2020.08.26.267831 [doi:10.1101/2020.08.26.267831](https://doi.org/10.1101/2020.08.26.267831) (2020). [Medline](#)
79. C. M. Voloch, R. da Silva F Jr, L. G. P. de Almeida, C. C. Cardoso, O. J. Brustolini, A. L. Gerber, A. P. de C. Guimarães, D. Mariani, R. M. da Costa, O. C. Ferreira Jr, A. C. Cavalcanti, T. S. Frauches, C. M. B. de Mello, R. M. Galliez, D. S. Faffe, T. M. P. P. Castiñeiras, A. Tanuri, A. T. R. de Vasconcelos, C.-U. Workgroup, LNCC-Workgroup, Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *J. Virol.* **10.1128/JVI.00119-21** (2020).
80. R. da Silva Francisco, L. Felipe Benites, A. P. Lamarca, L. G. P. de Almeida, A. W. Hansen, J. S. Gularte, M. Demoliner, A. L. Gerber, A. P. de C. Guimarães, A. K. E. Antunes, F. H. Heldt, L. Mallmann, B. Hermann, A. L. Ziulkoski, V. Goes, K. Schallenberger, M. Filippi, F. Pereira, M. N. Weber, P. R. de Almeida, J. D. Fleck, A. T. R. Vasconcelos, F. R. Spilki, Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. *Virus Res.* **296**, 198345 (2021).
81. V. B. Franceschi, G. D. Caldana, A. de Menezes Mayer, G. B. Cybis, C. A. M. Neves, P. A. G. Ferrareze, M. Demoliner, P. R. de Almeida, J. S. Gularte, A. W. Hansen, M. N. Weber, J. D. Fleck, R. A. Zimmerman, L. Kmetzsch, F. R. Spilki, C. E. Thompson, Genomic Epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil. *medRxiv* 21249906 [Preprint] 26 January 2021. [doi:10.1101/2021.01.21.21249906](https://doi.org/10.1101/2021.01.21.21249906)
82. B. Q. Minh, H. A. Schmidt, O. Chernomor, D. Schrempf, M. D. Woodhams, A. von Haeseler, R. Lanfear, IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020). [doi:10.1093/molbev/msaa015](https://doi.org/10.1093/molbev/msaa015) [Medline](#)
83. T. H. Jukes, C. R. Cantor, in *Mammalian Protein Metabolism*, H. N. Munro, Ed. (Academic Press, 1969), pp. 21–132.
84. R Core Team, R: A language and environment for statistical computing (R Core Team, Vienna, Austria, 2013).
85. M. Hasegawa, H. Kishino, T. Yano, Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. *J. Mol. Evol.* **22**, 160–174 (1985). [doi:10.1007/BF02101694](https://doi.org/10.1007/BF02101694) [Medline](#)
86. Z. Yang, Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: Approximate methods. *J. Mol. Evol.* **39**, 306–314 (1994). [doi:10.1007/BF00160154](https://doi.org/10.1007/BF00160154) [Medline](#)
87. M. A. Suchard, P. Lemey, G. Baele, D. L. Ayres, A. J. Drummond, A. Rambaut, Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.* **4**, vey016 (2018). [doi:10.1093/ve/vey016](https://doi.org/10.1093/ve/vey016) [Medline](#)
88. D. L. Ayres, A. Darling, D. J. Zwickl, P. Beerli, M. T. Holder, P. O. Lewis, J. P. Huelsenbeck, F. Ronquist, D. L. Swofford, M. P. Cummings, A. Rambaut, M. A. Suchard, BEAGLE: An application programming interface and high-performance computing library for statistical phylogenetics. *Syst. Biol.* **61**, 170–173 (2012). [doi:10.1093/sysbio/syr100](https://doi.org/10.1093/sysbio/syr100) [Medline](#)
89. A. Rambaut, A. J. Drummond, D. Xie, G. Baele, M. A. Suchard, Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Syst. Biol.* **67**, 901–904 (2018). [doi:10.1093/sysbio/syy032](https://doi.org/10.1093/sysbio/syy032) [Medline](#)
90. M. Worobey, T. D. Watts, R. A. McKay, M. A. Suchard, T. Granade, D. E. Teuwen, B. A. Koblin, W. Heneine, P. Lemey, H. W. Jaffe, 1970s and ‘Patient 0’ HIV-1 genomes illuminate early HIV/AIDS history in North America. *Nature* **539**, 98–101 (2016). [doi:10.1038/nature19827](https://doi.org/10.1038/nature19827) [Medline](#)
91. M. Bletsa, M. A. Suchard, X. Ji, S. Gryseels, B. Vrancken, G. Baele, M. Worobey, P. Lemey, Divergence dating using mixed effects clock modelling: An application to HIV-1. *Virus Evol.* **5**, vez036 (2019). [doi:10.1093/ve/vez036](https://doi.org/10.1093/ve/vez036) [Medline](#)
92. B. Murrell, J. O. Wertheim, S. Moola, T. Weighill, K. Scheffler, S. L. Kosakovsky Pond, Detecting individual sites subject to episodic diversifying selection. *PLOS Genet.* **8**, e1002764 (2012). [doi:10.1371/journal.pgen.1002764](https://doi.org/10.1371/journal.pgen.1002764) [Medline](#)
93. O. A. MacLean, S. Lytras, S. Weaver, J. B. Singer, M. F. Boni, P. Lemey, S. L. Kosakovsky Pond, D. L. Robertson, Evidence of significant natural selection in the evolution of SARS-CoV-2 in bats, not humans. *bioRxiv* 2020.05.28.122366 [doi:10.1101/2020.05.28.122366](https://doi.org/10.1101/2020.05.28.122366) (2020). [Medline](#)
94. A. G. Wrobel, D. J. Benton, P. Xu, C. Roustan, S. R. Martin, P. B. Rosenthal, J. J. Skehel, S. J. Gamblin, SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat. Struct. Mol. Biol.* **27**, 763–767 (2020). [doi:10.1038/s41594-020-0468-7](https://doi.org/10.1038/s41594-020-0468-7) [Medline](#)
95. L. Schrödinger. *The PyMOL Molecular Graphics*, version 2.0 (2015).
96. P. S. Peixoto, D. Marcondes, C. Peixoto, S. M. Oliva, Modeling future spread of infections via mobile geolocation data and population dynamics. An application to COVID-19 in Brazil. *PLOS ONE* **15**, e0235732 (2020). [doi:10.1371/journal.pone.0235732](https://doi.org/10.1371/journal.pone.0235732) [Medline](#)
97. T. Mellan, H. Hoeltgebaum, S. Mishra, C. Whittaker, R. P. Schnekenberg, A. Gandy, H. J. H. Unwin, M. A. Vollmer, H. Coupland, I. Hawryluk, N. R. Faria, J. Vesga, H. Zhu, M. Hutchinson, O. Ratmann, M. Monod, K. Ainslie, M. Baguelin, S. Bhatia, A. Boonyasiri, N. Brazeau, G. Charles, L. V. Cooper, Z. Cucunuba, G. Cuomo-Dannenburg, A. Dighe, B. Djafaara, J. Eaton, S. L. van Elsland, R. FitzJohn, K. Fraser, K. Gaythorpe, W. Green, S. Hayes, N. Imai, B. Jeffrey, E. Knock, D. Laydon, J. Lees, T. Mangal, A. Mousa, G. Nedjati-Gilani, P. Nouvellet, D. Olivera, K. V. Parag, M. Pickles, H. A. Thompson, R. Verity, C. Walters, H. Wang, Y. Wang, O. J. Watson, L. Whittles, X. Xi, L. Okell, I. Dorigatti, P. Walker, A. Ghani, S. Riley, N. Ferguson, C. A. Donnelly, S. Flaxman, S. Bhatt, Report 21: Estimating COVID-19 cases and

- reproduction number in Brazil. (Imperial College London, 2020); [doi:10.25561/78872](https://doi.org/10.25561/78872).
98. R. Bellman, T. Harris, *On Age-Dependent Binary Branching Processes*. In: *The Annals of Mathematics* (1952).
 99. W. Feller, On the Integral Equation of Renewal Theory. *Ann. Math. Stat.* **12**, 243–267 (1941). [doi:10.1214/aoms/1177731708](https://doi.org/10.1214/aoms/1177731708)
 100. I. Hawryluk, T. A. Mellan, H. Hoeltgebaum, S. Mishra, R. P. Schnakenberg, C. Whittaker, H. Zhu, A. Gandy, C. A. Donnelly, S. Flaxman, S. Bhatt, Inference of COVID-19 epidemiological distributions from Brazilian hospital data. *J. R. Soc. Interface* **17**, 20200596 (2020). [doi:10.1098/rsif.2020.0596](https://doi.org/10.1098/rsif.2020.0596) [Medline](#)
 101. J. Hellewell, T. W. Russell, R. Beale, G. Kelly, C. Houlihan, E. Nastouli, A. J. Kucharski, SAFER Investigators, Field Study Team, Crick COVID-19 Consortium, et al, Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. medRxiv 20229948 [Preprint] 24 December 2020. [doi:10.1101/2020.11.24.20229948](https://doi.org/10.1101/2020.11.24.20229948)
 102. B. Borremans, A. Gamble, K. C. Prager, S. K. Helman, A. M. McClain, C. Cox, V. Savage, J. O. Lloyd-Smith, Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. *eLife* **9**, e60122 (2020). [doi:10.7554/eLife.60122](https://doi.org/10.7554/eLife.60122) [Medline](#)

ACKNOWLEDGMENTS

We thank Lucy Matkin (University of Oxford), Marcio Oikawa (Universidade Federal do ABC) and Andre Acosta (University of Sao Paulo) for logistic support and Claudio Sachi (Instituto Adolfo Lutz) for agreeing with the use of unpublished sequence data available in GISAID before publication. We thank the anonymous reviewers for their considerations and suggestions. We thank the administrators of the GISAID database for supporting rapid and transparent sharing of genomic data during the COVID-19 pandemic. A full list acknowledging the authors publishing data used in this study can be found in Data S4. **Funding:** This work was supported by a Medical Research Council-São Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (caddecentre.org/); FAPESP (E.C.S.: 18/14389-0; I.M.C.: 2018/17176-8 and 2019/12000-1, F.C.S.S.: 2018/25468-9; J.G.J.: 2018/17176-8, 2019/12000-1, 18/14389-0; T.M.C.: 2019/07544-2; C.A.M.S.: 2019/21301-5; W.M.S.: 2017/13981-0, 2019/24251-9; L.M.S.: 2020/04272-9; M.C.P.: 2019/21568-1; V.H.N.: 2018/12579-7; C.A.P.J.: 2019/21858-0; and P.S.P.: 16/18445-7; J.L.P.-M.: 2020/04558-0); Wellcome Trust and Royal Society (N.R.F. Sir Henry Dale Fellowship: 204311/Z/16/Z); Wellcome Trust (Wellcome Centre for Human Genetics: 203141/Z/16/Z); Clarendon Fund and Department of Zoology, University of Oxford (D.S.C.); Medical Research Council (T.A.B. R.J.G.H: MR/S007555/1); European Molecular Biology Organisation (R.J.G.H.: ALTF 869-2019); CNPq (R.S.A.: 312688/2017-2, 439119/2018-9; W.M.S.: 408338/2018-0, 304714/2018-6; V.H.N.: 304714/2018-6); FAPERJ (R.S.A.: 202.922/2018). FFMUSP (M.S.R.: 206.706; C.A.P.J.); Imperial College Covid-19 Research Fund (H.S.; S.F.); CAPES (G.M.F.: C.A.P.J. Code 001); Wellcome Trust Collaborator Award (P.L., A.R., and N.J.L.: 206298/Z/17/Z); European Research Council (P.L. and A.R.: 725422-ReservoirDOCS); European Union's Horizon 2020 project MOOD (P.L. and M.U.G.K.: 874850); US National Institutes of Health (M.A.S.: U19 AI135995); Oxford Martin School (O.G.P.); Branco Weiss Fellowship (M.U.G.K.); Covid-19 Research Fund (S.F.); EPSRC (S.F.: EP/V002910/1; M.M. through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning); BMGF (S.B.), UKRI (S.B.), Novo Nordisk Foundation (S.B.); Academy of Medical Sciences (S.B.), BRC (S.B.) and MRC (S.B.); Bill & Melinda Gates foundation (O.R.: OPP1175094). We acknowledge support from the Rede Corona-ômica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/2020-4), FAPESP Proj. no. 2018/12579-7 CNPq Proj. no. 304714/2018-6 (V.N.) EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford (M.M.). Bill & Melinda Gates foundation (OPP1175094)(O.R.). This work received funding from the UK Medical Research Council under a concordat with the UK Department for International Development. We additionally acknowledge support from Community Jameel and the NIHR Health Protection Research Unit in Modelling Methodology. Last, we also gratefully acknowledge support from Oxford Nanopore Technologies for a donation of sequencing reagents and NVIDIA Corporation and Advanced Micro Devices, Inc., for a donation of parallel

computing resources. **Author contributions:** Conceptualization: NRF, TAM, CW, ICM, DSC, AR, CD, OGP, SF, SB, ECS. Methodology: NRF, TAM, CW, TAM, ICM, DSC, SM, FCS, IH, MSR, JGJ, LAMF, PSA, TMC, CAMS, ERM, JTM, RHM, PSP, MUGK, RH, TB, OGP, MS, SP, OR, NF, NJL, PL, AR, CD, OGP, SF, SM, ECS. Investigation: NRF, TAM, CW, IMC, DSC, SM, MAEC, FCSS, IH, MSR, JGJ, LAMF, PSA, TMC, CAMS, ERM, JTM, RHMP, PSP, MUGK, RH, NG, WMS, LJTA, CCC, HH, GMF, ECR, LMS, MCP, FSVM, ABL, JPS, DAGZ, ACSF, RPS, DJL, PGTW, HS, ALPS, MSV, CCC, VSDC, RMFF, HMS, RSA., BN, JH, MM, XM, HC, RS, AG, MS, TB, SP, CHW, OR, NMF, CPJ, VHN, NJL, PL, AR, NAF, MPSSC, CD, OGP, SF, SB, ECS. Visualization: NRF, TAM, CW, DSC, IMC, JT, AR, SP, TB, CW, SB. Funding acquisition: NRF, NL, AR, OGP, NF, SF, SB, ECS. Project administration: NRF, ECS. Supervision: NRF, OGP, AR, CD, NL, SB, ECS Writing – original draft: NRF, TM, CW, IMC, DSC, SF, SB, OGP, CD, ECS. Writing – review and editing: All authors. **Competing interests:** S.B. declares he advises on The Scientific Pandemic Influenza Group on Modelling (SPI-M) and advises the FCA on a legal matter regarding COVID-19 infections in England in March 2020. He is not paid for either of these advisory roles, and neither are related to the work in this paper. All other authors declare that they have no competing interests. **Data and materials availability:** All data, code, and materials used in the analysis are available in a dedicated GitHub Repository (64, 65). This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. Data and materials are available in (64, 65).

SUPPLEMENTARY MATERIALS

science.sciencemag.org/cgi/content/full/science.abh2644/DC1

Materials and Methods

Supplementary Text

Figs. S1 to S16

Tables S1 to S10

References (70–102)

MDAR Reproducibility Checklist

Data Files S1 to S6

25 February 2021; accepted 11 April 2021

Published online 14 April 2021

10.1126/science.abh2644

Fig. 1. SARS-CoV-2 epidemiological, diagnostic, genomic and mobility data from Manaus. (A) Dark solid line shows the 7-day rolling average of the COVID-19 confirmed and suspected daily time series of hospitalisations in Manaus. Admissions in Manaus are from Fundação de Vigilância em Saúde do Amazonas (66). Green dots represent daily severe acute respiratory mortality records from the SIVEP-Gripe (*Sistema de Informação de Vigilância Epidemiológica da Gripe*) database (67). SARI = severe acute respiratory infections. Excess burial records based on data from Manaus Mayor's office are shown in red dots for comparison (see Materials and Methods). The arrow denotes 6 December 2020, the date of the first P.1 case identified in Manaus by our study. (B) Maximum likelihood tree ($n=962$) with B.1.1.28, P.1 and P.2 sequences, with collapsed views of P.1 and P.2 clusters and highlighting other sequences from Manaus, Brazil). Ancestral branches leading to P.1 and P.2 are shown as dashed lines. See fig. S3 for a more detailed phylogeny. Scale bar is shown in units of nucleotide substitutions per site (s/s). (C) Number of air travel passengers from Manaus to all states in Brazil was obtained from National Civil Aviation Agency of Brazil (www.gov.br/anac). The ISO 3166-2:BR codes of the states with genomic reports of P.1 (GISAID (68), as of 24 Feb 2021), are shown in bold. An updated list of GISAID genomes and reports of P.1 worldwide is available at https://cov-lineages.org/global_report_P.1.html. (D) Number of genome sequences from Manaus belonging to lineages of interest (see Materials and Methods); spike mutations of interest are denoted.

Fig. 2. Visualization of the time-calibrated maximum clade credibility tree reconstruction for B.1.1.28, P.1 and P.2 lineages ($n = 962$) in Brazil. Terminal branches and tips of Amazonas state are colored in brown and those from other locations are colored in green. Nodes with posterior probabilities of < 0.5 have been collapsed into polytomies and their range of divergence dates are illustrated as shaded expanses.

Fig. 3. Temporal variation in the proportion of sequenced genomes belonging to P.1, and trends in RT-qPCR Ct values for COVID-19 infections in Manaus. (A) Logistic function fitting to the proportion of genomes in sequenced infections that have been classified as P.1 (black circles, size indicating number of infections sequenced), divided up into time-periods where the predicted proportion of infections that are due to P.1 is $<1/3$ (light brown), between $1/3$ and $2/3$ (green) and greater than $2/3$ (grey). For the model fit, darker ribbon represents the 50% credible interval, and lighter ribbon represents the 95% credible interval. For the data points, grey thick line is the 50% exact Binomial confidence interval and the thinner line is the 95% exact Binomial confidence interval. (B) Ct values for genes *E* and *N* in a sample of symptomatic cases presenting for testing at a healthcare facility in Manaus (laboratory A), stratified according to the period defined in (A) in which the oropharyngeal and nasal swab collections occurred in. (C) Ct values for genes *E* and *N* in a subsample of 184 infections included in (B) that had their genomes sequenced (dataset A).

Fig. 4. Estimates of the epidemiological characteristic of P.1 inferred from a multicategory Bayesian transmission model fitted to data from Manaus, Brazil. (A) Joint posterior distribution of the cross-immunity and transmissibility increase inferred through fitting the model to mortality and genomic data. Grey contours refer to posterior density intervals ranging from the 95% and 50% isoclines. Marginal posterior distributions for each parameter shown along each axis. (B) As for (A) but showing the joint-posterior distribution of cross-immunity and the inferred relative risk of mortality in the period following emergence of P.1 compared to the period prior. (C) Daily incidence of COVID-19 mortality. Points show severe acute respiratory mortality records from the SIVEP-Gripe database (67, 69), brown and green ribbons show model fit for COVID-19 mortality incidence, disaggregated by mortality attributable to non-P.1 lineages (brown) and the P.1 lineage (green). (D) Estimate of the proportion of P.1 infections through time in Manaus. Black data points with error bars are the empirical proportion observed in genomically sequenced cases (see Fig. 3A) and green ribbons (dark = 50% BCI, light = 95% BCI) the model fit to the data. (E) Estimated cumulative infection incidence for the P.1 and non-P.1 categories. Black data points with error bars are reversion-corrected estimates of seroprevalence from blood donors in Manaus (2), colored ribbons are the model predictions of cumulative infection incidence for non-P.1 lineages (brown) and P.1 lineages (green). These points are shown for reference only and were not used to fit the model. (F) Bayesian posterior estimates of trends in reproduction number R_t for the P.1 and non-P.1 categories.